Biopharmaceutical News and Research

RSS

Leeches, useful tools in the treatment of cardiovascular diseases

The leech has recently confirmed its biomedical interest for scientists by showing that it contains an extensive list of new potential molecules that may become useful tools in the treatment of cardiovascular diseases.

24 Oct 2005

A DNA-based vaccine could be a potent weapon against bird flu

Researchers scrambling to combat a virulent form of bird flu that could mutate into a form easily spread among humans should consider developing vaccines based on DNA, according to British biochemical engineers.

19 Oct 2005

Ischemic brain injury - another promising avenue for stem cell therapy

Adult stem cell therapy quickly and significantly improves recovery of motor function in an animal model for the ischemic brain injury that occurs in about 10 percent of babies with cerebral palsy, researchers report.

4 Oct 2005

Increlex - first major innovation in 20 years for the treatment of growth failure

Rush University Medical Center is participating in a clinical trial to evaluate the potential benefit of the first major innovation in 20 years for the treatment of growth failure.

26 Sep 2005

Microchip system aims to reduce the number of animals used in the development of new drugs

Reducing the number of animals used in the development of new drugs is a priority for the pharmaceutical industry

26 Sep 2005

Simple organism can produce 10 trillion varieties of a single protein

A team led by University of California, San Diego biochemists has discovered the mechanism by which a simple organism can produce 10 trillion varieties of a single protein, a finding that provides a new tool to develop novel drugs.

21 Sep 2005

Domantis successful in patent opposition

Domantis Limited, the human Domain Antibody Therapeutics company, has successfully opposed European patent number EP0656946, leading to a major amendment of the main claim in the patent and a significant narrowing of the scope of 34 of the 41 other claims.

1 Sep 2005

European Rare Diseases Therapeutic Initiative could provide an important new mechanism for developing new drugs

Because of the very high costs in developing drugs for rare genetic diseases, and the low return on investment, the pharmaceutical industry has rarely developed specific treatments for many of these diseases.

23 Aug 2005

Successful visceral leishmaniasis vaccine trial in dog

Visceral leishmaniasis, which is the most severe form of that group of diseases, affects 500 000 people in the world each year. It is caused by a protozoan, Leishmania infantum, transmitted by sand fly bites.

2 Aug 2005

Most undergraduate doctors in the UK receive only 5 minutes education on sleep medicine

Teaching staff at Warwick Medical School have long been concerned that trainee doctors do not get enough sleep. Sleep in the classroom that is. Despite sleep patterns being a major contributor to a number of illnesses on average most undergraduate doctors in the UK receive only 5 minutes education on sleep medicine.

28 Jul 2005

Role of IL-24 in regulating the immune system

Researchers at Introgen Therapeutics and their collaborators at The University of Texas M. D. Anderson Cancer Center have published new findings on the role of IL-24 in regulating the immune system in the current online issue of the Journal of Leukocyte Biology.

21 Jul 2005

Results demonstrate the safety and tolerability of ABthrax treatment for Anthrax infection

Human Genome Sciences has announced that results published in the current issue of Clinical Infectious Diseases demonstrate that the first investigational agent against anthrax infection to be evaluated in a clinical study since the 2001 anthrax attacks in the United States, is safe, well tolerated and achieves the blood levels predicted by relevant animal models as necessary to afford significant protection from the lethal effects of the anthrax toxin

19 Jul 2005

Chromos Molecular Systems issued four key patents

Chromos Molecular Systems has announced that it has further expanded the patent portfolio surrounding both its ACE System and REM Technology with the issuance of four key additional patents.

15 Jul 2005

Nanotechnology used to smuggle a powerful chemotherapeutic drug inside tumor cells

University of Michigan scientists have created the nanotechnology equivalent of a Trojan horse to smuggle a powerful chemotherapeutic drug inside tumor cells - increasing the drug's cancer-killing activity and reducing its toxic side effects.

15 Jun 2005

One-a-day tablet treats common infection

A bioadhesive tablet containing the antifungal drug miconazole is an effective and convenient means of treating oropharyngeal candidiasis, which is the most frequently occurring infection in head and neck cancer patients undergoing radiation therapy, scientists reported at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.

6 Jun 2005

Targepeutics issued new U.S patent

Targepeutics has announced the issuance of U.S. Patent No. 6,884,603 for its genetically modified, mutated Interleukin 13 (IL-13) technology platform for the treatment of malignant glioma, a brain tumor (17,500 people annually; $200 million annual market).

31 May 2005

Bioniche granted additional patent for mycobacterial cell wall technology

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had a new patent issued by the United States Patent and Trademark Office (USPTO) on its core mycobacterial cell wall technology.

18 May 2005

National study to evaluate the effectiveness Targacept

Wake Forest University School of Medicine is one of 15 centers nationwide recruiting participants for a research study to evaluate the effectiveness of an investigational drug as an oral treatment for age associated memory impairment (AAMI), a condition that is marked by memory loss and poor concentration.

27 Apr 2005

REPLICor to disclose unique antiviral drug

REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.

30 Mar 2005

Bioniche receives European patent

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had an additional European patent granted by the European Patent Office (EPO) on its core mycobacterial cell wall technology.

29 Mar 2005